Linked Life Data

19902821

Source:http://linkedlifedata.com/resource/pubmed/id/19902821

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-11-11
pubmed:abstractText
Glioblastoma (GBM) is the most malignant primary brain tumour in adults. Since 2005 surgery followed by radiotherapy with concomitant Temozolomide (TMZ) is the standard care for patients with a GBM. Despite these improved treatment strategies, survival of GBM-patients remains poor; and there are very few patients who survive for a long time. Also there is no standard therapeutic strategy after six cycles of TMZ, and further treatment is at the physician's discretion. We report a case of a young patient with a glioblastoma who, not only showed dramatic clinical and radiological improvement after TMZ treatment but who now also (under continued TMZ therapy) survives over 6 years, with complete remission clinically and radiologically. Up till now there are no studies describing TMZ treatment in GBM patients for as long as 6 years.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0300-9009
pubmed:author
pubmed:issnType
Print
pubmed:volume
109
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
238-42
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
pubmed:affiliation
Dept. of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. jpoelen@hotmail.com
pubmed:publicationType
Journal Article, Case Reports